Clinical trial

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

NCT06397703

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-04-16

PhasePHASE2

Study timeline

Study start (actual)2024-04-16Date precision: day

Registry last updated2026-01-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Leuprolide, Degarelix or RelugolixDRUG

Stereotactic body radiation therapy/radiosurgery (SBRT)RADIATION

Sponsors & collaborators

NYU Langone Healthlead sponsor

Mapped research locations

New YorkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06397703 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.